Ivonescimab, a first-in-class humanized bispecific antibody targeting both programmed cell death protein 1(PD-1) and vascular endothelial growth factor A (VEGF-A), enhances therapeutic efficacy in NSCLC by simultaneously inhibiting PD-1/PD-L1–mediated immune escape and VEGF-driven angiogenesis. Here, VEGFA is linked to non-small cell lung carcinoma.